Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol

American Journal of the Medical Sciences

Volumn 345, Issue 3, 2013, Pages 195-199

  Hamoud, Shadi ^a,b   Kaplan, Marielle ^b   Meilin, Edna ^b   Hassan, Ahmad ^a   Torgovicky, Rafael ^c   Cohen, Raanan ^c   Hayek, Tony ^a,b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Atherosclerosis; HDL; Hypercholesterolemia; Niacin; Oxidative stress

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SIMVASTATIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; FLUSHING; HUMAN; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRURITUS; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84874652548     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182548c28     Document Type: Article

References (39)

1. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 1994;344:721-4.
2. Kaplan M, Aviram M. Oxidized low density lipoprotein atherogenic and proinflammatory characteristics during macrophage foam cell formation: an inhibitory role for nutritional antioxidants and serum paraoxonase. Clin Chem Lab Med 1999;37:777-87.
3. Aviram M. Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. Free Radic Res 2000; 33(suppl):S85-97.
4. Chapman MJ. The potential role of HDL-and LDL-cholesterol modulation in atheromatous plaque development. Curr Med Res Opin 2005; 21(suppl 6):S17-22.
5. Dragsted LO. Antioxidant actions of polyphenols in humans. Int J Vitam Nutr Res 2003;73:112-9.
6. Aviram M, Kaplan M, Rosenblat M, et al. Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. Handb Exp Pharmacol 2005;(170):263-300.
7. Nigdikar SV, Williams NR, Griffin BA, et al. Consumption of red wine polyphenols reduces the susceptibility of low-density lipoproteins to oxidation in vivo. Am J Clin Nutr 1998;68:258-65.
8. Aviram M, Fuhrman B. Wine flavonoids protect against LDL oxidation and atherosclerosis. Ann N Y Acad Sci 2002;957:146-61.
9. Aviram M, Dornfeld L, Rosenblat M, et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 2000;71:1062-76.
10. Kaplan M, Hayek T, Raz A, et al. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J Nutr 2001;131:2082-9.
11. Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr 2004;23:423-33.
12. Erratum in: Clin Nutr 2008;27:671
13. Vaya J, Belinky PA, Aviram M. Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation. Free Radic Biol Med 1997;23:302-13.
14. Belinky PA, Aviram M, Fuhrman B, et al. The antioxidative effects of the isoflavan glabridin on endogenous constituents of LDL during its oxidation. Atherosclerosis 1998;137:49-61.
15. Kamanna VS, Kashyap ML. Mechanism of action of niacin [review]. Am J Cardiol 2008;101:20B-26B.
16. Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular apo B degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (Hep G2) cells. Arterioscler Thromb Vasc Biol 1999; 19:1051-9.
17. Ganji SH, Tavintharan S, Zhu D, et al. Niacin non-competitively inhibits FGAT2 but not DGAT1 activity in Hep G2 cells. J Lipid Res 2004;45:1835-45.
18. Wang W, Basinger A, Neese RA, et al. Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am J Physiol Endocrinol Metab 2001;280:E540-7.
19. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
20. Olsson AG. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease. Expert Opin Pharmacother 2010;11:1715-26.
21. Blum CB, Levy RI, Eisenberg S, et al. High density lipoprotein metabolism in man. J Cin Invest 1977;60:795-807.
22. Shepherd J, Packard CJ, Patsch JR, et al. Effect of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979; 63:858-67.
23. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implications for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997;17:2020-8.
24. Zhang LH, Kamanna VS, Zhang MC, et al. Niacin inhibits surface expression of ATP synthase beta chain in Hep G2 cells: implications for raising HDL. J Lipid Res 2008;49:1195-201.
25. Aviram M, Vaya J. Markers for low-density lipoprotein oxidation. Methods Enzymol 2001;335:244-56.
26. El-Saadani M, Esterbauer M, El-Sayed M, et al. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res 1989;30:627-30.
27. Gan KN, Smolen A, Eckerspn HW, et al. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100-6.
28. Gandotra P, Miller M. The role of triglycerides in cardiovascular risk. Curr Cardiol Rep 2008;10:505-11.
29. Chapman MJ, Assmann G, Fruchart JC, et al. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004;20:1253-68.
30. Maron DJ. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol 2000;86:11L-14L.
31. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2001;104:1108-13.
32. Gotto AM Jr, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 2004;43:717-24.
33. Grundy SM, Mok HYI, Zech L, et al. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981; 22:24-36.
34. Ganji SH, Qin S, Zhang L, et al. Niacin inhibits vascular oxidative stress, redox-sensitive genes and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009;202:68-75.
35. Schieffer B. Interaction of interleukin-6 and angiotensin II in atherosclerosis: culprit for inflammation? Eur Heart J 2003;5(suppl A): A25-30.
36. Accini R, Rosina M, Bamonti F, et al. Effects of combined dietary supplementation on oxidative stress and inflammatory status in dyslipidemic patients. Nutr Metab Cardiovasc Dis 2006;16:121-7.
37. Kantash A, Chapman J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol Rev 2006;58:342-74.
38. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581-90.
39. Aviram M, Billecke S, Sorenson R, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998;18:1617-24.